| Project/Area Number |
15K15087
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pathological medical chemistry
|
|---|
| Research Institution | University of Miyazaki |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
中畑 新吾 宮崎大学, 医学部, 助教 (80437938)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 腸内細菌叢 / HTLV-1 / ATL / 成人T細胞白血病 |
|---|
| Outline of Final Research Achievements |
To study the involvement of gut microbiota in ATL leukemogenesis, we performed a comprehensive intestinal microbiota analysis by next generation sequencing of 16S rDNA using stool samples from 11 healthy volunteers and 16 patients with acute-type ATL. We found that the population of Bifidobacterium, one of the important bacteria for the host immune activity, was significantly decreased in ATL patients, suggesting that the reduced Bifidobacterium species is partly involved in the opportunistic infections observed in ATL patients. Moreover, some of opportunistic bacteria such as Bacteroides were found to be increased in ATL patients. Because these alterations in gut microbiota can be caused by the infiltrated HTLV-1-infected T-cells into the gut, the resulting disturbances in the gut bacteria may contribute to ATL cell growth through deregulation of cytokine production, which may be an invaluable molecular target for ATL therapy.
|
